Acción PV3B EYEPOINT PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Acciones

PV3B

US30233G2093

Tiempo real estimado Tradegate
Otros sitios de cotización
 14:40:37 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
7,951 EUR +1,24 % Gráfico intradía de EyePoint Pharmaceuticals, Inc. -5,58 % -64,55 %
12/06 Transcript : EyePoint Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
04/06 EYEPOINT PHARMACEUTICALS, INC. : JPMorgan Chase da una recomendación de compra ZM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals : Goldman Sachs Global Healthcare Conference Presentation
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
EyePoint Pharmaceuticals : Investor Presentation May 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation
Sector Update: Health Care Stocks Gain Pre-Bell Monday
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals, Inc. Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción EYPT
  4. Acción PV3B
  5. Noticias EyePoint Pharmaceuticals, Inc.
  6. Otros idiomas